Corient Private Wealth LLC Has $1.02 Million Position in Insmed Incorporated (NASDAQ:INSM)

Corient Private Wealth LLC raised its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 34.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,730 shares of the biopharmaceutical company's stock after acquiring an additional 3,747 shares during the quarter. Corient Private Wealth LLC's holdings in Insmed were worth $1,017,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INSM. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management acquired a new position in shares of Insmed during the 4th quarter worth about $47,000. Smartleaf Asset Management LLC grew its holdings in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Insmed in the fourth quarter valued at about $86,000.

Analyst Upgrades and Downgrades

Several brokerages recently commented on INSM. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. Bank of America boosted their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Truist Financial increased their price target on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company lifted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Remove Ads

Insmed Stock Performance

Shares of Insmed stock traded up $0.30 on Friday, hitting $77.99. The stock had a trading volume of 950,343 shares, compared to its average volume of 2,230,931. The stock has a market cap of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The business's 50 day moving average is $78.18 and its two-hundred day moving average is $74.00.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $25,742,347.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 550,957 shares of company stock worth $42,992,528. Corporate insiders own 4.60% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.